Triple-Therapy With PegInterferon alpha-2b + Ribavirin + Boceprevir in Patients With HCV Genotype 3 Who Previously Failed Treatment With PegInterferon alpha + Ribavirin

Trial Profile

Triple-Therapy With PegInterferon alpha-2b + Ribavirin + Boceprevir in Patients With HCV Genotype 3 Who Previously Failed Treatment With PegInterferon alpha + Ribavirin

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon alfa-2b (Primary) ; Peginterferon; Peginterferon alfa-2b/ribavirin; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms LeeG3
  • Most Recent Events

    • 28 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jan 2014 Planned End Date changed from 1 May 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 21 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top